For Immediate Release
Chicago, IL – December 6, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Home Depot (HD - Free Report) , Boeing (BA - Free Report) , Merck (MRK - Free Report) , Allstate (ALL - Free Report) and Illumina (ILMN - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Home Depot, Boeing and Merck
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Home Depot, Boeing and Merck. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-rated Home Depot’s shares have gained +37.9% year to date, compared with the +31.5% gain of the Zacks Retail Building Products industry, backed by its five-year long trend of beating earnings estimates. The company delivered bottom-line beat in third-quarter fiscal 2017, while sales topped estimates for the fifth straight quarter.
Results gained from strength in core business as well as relentless focus on affording innovative products, boosting interconnected customer experience and driving productivity. Steady housing market recovery and strong customer demand also remained tailwinds.
While hurricane-related activities aided comps growth, gross margins on such sales were significantly below average. This led to a decline in gross margin, which is likely to continue in fiscal 2017. Moreover, competition from online retailers may impact performance.
Shares of Boeing have surged +78.6% over the past year, outperforming the Zacks Aerospace & Defense sector, which gained +39.2% during the same time period. Notably, Boeing is the largest aircraft manufacturer in the world in terms of revenue, orders and deliveries, and one of the largest aerospace and defense contractors.
In this regard, the company’s 20-year market outlook forecasts commercial jetliner demand to increase by 3.6%. Yet, this aerospace company continues to face challenges from order cancellations, stiff competition as well as falling delivery numbers. Furthermore, Boeing’s 787 Dreamliner's deferred production cost remains a cause of concern.
Merck’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the last year, losing -6.8% versus +18.5%, as the company has suffered some notable pipeline setbacks this year. Merck enjoys a diversified business across branded drugs, vaccines and animal health.
Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to the top line. Keytruda is gaining strong momentum from new indication of first-line lung cancer. The Keytruda development program also significantly advanced this year with several key regulatory approvals.
Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern.
Other noteworthy reports we are featuring today include Allstate and Illumina.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.